4DMT's One-Shot Eye Therapy Holds Up at Two Years in Wet AMD

4D Molecular Therapeutics delivered the kind of durability data gene-therapy investors have been waiting for in eye disease. The company (NASDAQ: FDMT) is developing 4D-150, a one-time intravitreal gene therapy designed to reduce the relentless injection burden faced by patients with wet age-related macular degeneration.

On July 18, 2026, 4DMT presented positive two-year data from its PRISM Phase 2b trial in a broad wet AMD population at the American Society of Retina Specialists meeting. Best-corrected visual acuity and central subfield thickness were maintained through two years, and patients achieved a 78% reduction in overall treatment burden, averaging just 2.7 supplemental anti-VEGF injections versus a projected 12. Across 71 patients treated at the Phase 3 dose, only 2.8% experienced mild, transient intraocular inflammation within the first 28 weeks, with no new cases afterward. The results support the ongoing 4FRONT global Phase 3 registration program.

Mid-stage durability does not guarantee success in larger pivotal trials, where gene-therapy safety and efficacy face a higher bar. This is market commentary, not investment advice — small-cap biotech stocks are highly speculative and you can lose your entire investment.